Pacific Biosciences of California (PACB) Financials

$0.98 -0.04 (-3.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.98 +0.00 (+0.39%)

As of 07:49 PM Eastern

Annual Income Statements for Pacific Biosciences of California

This table shows Pacific Biosciences of California's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-310	-307	-314
Consolidated Net Income / (Loss)	-310	-307	-314
Net Income / (Loss) Continuing Operations	-310	-307	-314
Total Pre-Tax Income	-310	-318	-314
Total Operating Income	-474	-334	-307
Total Gross Profit	37	53	49
Total Revenue	308	201	128
Operating Revenue	308	201	128
Total Cost of Revenue	117	148	79
Operating Cost of Revenue	116	148	79
Total Operating Expenses	512	387	356
Selling, General & Admin Expense	175	170	161
Research & Development Expense	135	187	193
Amortization Expense	18	6.16	0.00
Impairment Charge	185	0.00	0.00
Restructuring Charge	0.00	9.04	0.00
Other Special Charges / (Income)	-0.85	15	2.38
Total Other Income / (Expense), net	10	16	-7.05
Interest Expense	13	16	15
Other Income / (Expense), net	24	33	7.64
Income Tax Expense	0.32	-11	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	-0.20	-	-
Basic Earnings per Share	($1.13)	($1.21)	($1.40)
Weighted Average Basic Shares Outstanding	274.49M	253.63M	224.55M
Diluted Earnings per Share	($1.59)	($1.21)	($1.40)
Weighted Average Diluted Shares Outstanding	288.37M	253.63M	224.55M
Weighted Average Basic & Diluted Shares Outstanding	297.85M	267.95M	247.08M
Cash Dividends to Common per Share	$0.00	$0.00	-

This table shows Pacific Biosciences of California's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	1.24	-59	-174	-79	-85	-66	-71	-85	-84	-78
Consolidated Net Income / (Loss)	2.37	-61	-173	-78	-82	-67	-70	-88	-84	-77
Net Income / (Loss) Continuing Operations	2.37	-61	-173	-78	-82	-67	-70	-88	-85	-77
Total Pre-Tax Income	2.69	-61	-173	-78	-83	-78	-70	-88	-84	-77
Total Operating Income	-153	-64	-176	-81	-88	-82	-73	-91	-87	-75
Total Gross Profit	10	10	5.94	11	9.57	18	16	9.76	5.14	14
Total Revenue	193	40	36	39	58	56	48	39	27	32
Operating Revenue	193	40	36	39	58	56	48	39	27	32
Total Cost of Revenue	29	30	30	28	49	38	32	29	22	19
Operating Cost of Revenue	29	30	29	28	49	38	32	29	22	19
Total Operating Expenses	163	74	182	93	97	100	89	101	92	88
Selling, General & Admin Expense	42	44	46	44	46	43	41	40	45	37
Research & Development Expense	27	26	38	43	45	48	46	49	43	47
Amortization Expense	4.63	3.65	4.22	5.51	5.42	0.74	0.00	0.00	-	-
Other Special Charges / (Income)	-1.95	1.17	0.00	-0.07	1.10	-0.27	1.98	12	4.60	4.28
Total Other Income / (Expense), net	1.31	3.35	2.53	3.18	4.81	4.92	3.34	3.24	2.96	-2.35
Interest Expense	2.76	3.54	3.54	3.58	3.57	3.59	5.59	3.63	3.65	3.66
Other Income / (Expense), net	4.07	6.89	6.07	6.76	8.38	8.51	8.93	6.87	-	1.31
Income Tax Expense	0.32	0.00	0.00	0.00	-0.72	-11	0.00	0.00	-	0.00
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	1.13	-2.08	0.22	0.53	-	-0.85	0.76	-2.84	-	0.80
Basic Earnings per Share	$0.02	($0.22)	($0.64)	($0.29)	($0.31)	($0.26)	($0.28)	($0.36)	($0.37)	($0.34)
Weighted Average Basic Shares Outstanding	274.49M	272.92M	272.39M	269.58M	253.63M	255.00M	250.07M	242.03M	224.55M	225.12M
Diluted Earnings per Share	($0.44)	($0.22)	($0.64)	($0.29)	($0.31)	($0.26)	($0.28)	($0.36)	($0.37)	($0.34)
Weighted Average Diluted Shares Outstanding	288.37M	272.92M	272.39M	269.58M	253.63M	255.00M	250.07M	242.03M	224.55M	225.12M
Weighted Average Basic & Diluted Shares Outstanding	297.85M	273.86M	272.53M	272.36M	267.95M	267.44M	250.56M	249.89M	247.08M	226.11M

This table details how cash moves in and out of Pacific Biosciences of California's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-125	-146	-138
Net Cash From Operating Activities	-206	-259	-263
Net Cash From Continuing Operating Activities	-206	-259	-263
Net Income / (Loss) Continuing Operations	-310	-307	-314
Consolidated Net Income / (Loss)	-310	-307	-314
Depreciation Expense	14	11	9.48
Amortization Expense	27	2.23	7.59
Non-Cash Adjustments To Reconcile Net Income	105	89	86
Changes in Operating Assets and Liabilities, net	-42	-55	-52
Net Cash From Investing Activities	124	4.60	116
Net Cash From Continuing Investing Activities	124	4.60	116
Purchase of Property, Plant & Equipment	-6.19	-8.84	-17
Acquisitions	0.00	-0.10	-0.18
Purchase of Investments	-499	-757	-443
Sale and/or Maturity of Investments	629	770	576
Net Cash From Financing Activities	-43	109	9.62
Net Cash From Continuing Financing Activities	-43	109	9.62
Repayment of Debt	-0.49	-9.22	-1.61
Issuance of Common Equity	7.70	205	11
Other Financing Activities, net	-50	-86	0.00
Cash Interest Paid	15	16	14

This table details how cash moves in and out of Pacific Biosciences of California's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-23	-22	22	-103	-206	176	-145	29	21	-6.01
Net Cash From Operating Activities	-31	-45	-54	-76	-58	-65	-42	-95	-61	-63
Net Cash From Continuing Operating Activities	-31	-45	-54	-76	-58	-65	-42	-95	-61	-62
Net Income / (Loss) Continuing Operations	2.37	-61	-173	-78	-82	-67	-70	-88	-84	-77
Consolidated Net Income / (Loss)	2.37	-61	-173	-78	-82	-67	-70	-88	-84	-77
Depreciation Expense	2.84	4.19	3.50	3.24	2.98	2.90	2.83	2.76	2.54	2.35
Amortization Expense	5.73	8.82	7.25	4.74	5.97	-1.42	-1.92	-0.39	0.69	6.13
Non-Cash Adjustments To Reconcile Net Income	-48	18	115	20	23	24	21	22	22	17
Changes in Operating Assets and Liabilities, net	6.21	-16	-6.33	-25	-7.36	-24	6.48	-31	-1.08	-10
Net Cash From Investing Activities	58	23	77	-34	-67	242	-99	-73	80	54
Net Cash From Continuing Investing Activities	58	23	77	-34	-67	242	-99	-73	80	54
Purchase of Property, Plant & Equipment	-1.62	0.79	-1.48	-3.88	-2.02	-0.83	-2.27	-3.72	-4.90	-4.19
Purchase of Investments	-80	-115	-112	-192	-203	-77	-244	-233	-135	-67
Sale and/or Maturity of Investments	140	137	190	162	138	320	147	164	220	125
Net Cash From Financing Activities	-50	0.81	-0.15	6.55	-82	-0.78	-4.72	196	0.82	3.13
Net Cash From Continuing Financing Activities	-50	0.81	-0.15	6.55	-82	-0.78	-4.72	196	0.82	3.13
Other Financing Activities, net	-50	-	-	-	-82	-	-	-	-	-

This table presents Pacific Biosciences of California's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,260	1,746	1,767
Total Current Assets	496	742	852
Cash & Equivalents	55	180	325
Restricted Cash	0.69	0.30	0.30
Short-Term Investments	335	452	447
Accounts Receivable	28	37	19
Inventories, net	59	57	50
Prepaid Expenses	19	17	10
Plant, Property, & Equipment, net	31	36	42
Total Noncurrent Assets	734	968	873
Goodwill	318	462	410
Intangible Assets	390	457	410
Other Noncurrent Operating Assets	25	46	50
Other Noncurrent Nonoperating Assets	1.53	2.42	2.92
Total Liabilities & Shareholders' Equity	1,260	1,746	1,767
Total Liabilities	754	1,045	1,204
Total Current Liabilities	66	95	263
Accounts Payable	17	15	12
Accrued Expenses	23	46	33
Current Deferred Revenue	14	16	30
Other Current Liabilities	13	18	16
Total Noncurrent Liabilities	688	950	941
Long-Term Debt	647	892	897
Noncurrent Deferred Revenue	5.90	5.53	1.79
Other Noncurrent Operating Liabilities	34	52	42
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	507	701	563
Total Preferred & Common Equity	507	701	563
Preferred Stock	0.00	0.00	0.00
Total Common Equity	507	701	563
Common Stock	2,655	2,540	2,100
Retained Earnings	-2,149	-1,839	-1,532
Accumulated Other Comprehensive Income / (Loss)	0.42	0.22	-4.77

This table presents Pacific Biosciences of California's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,450	1,509	1,670	1,898	1,848	1,896	1,819
Total Current Assets	584	628	677	882	936	981	914
Cash & Equivalents	78	100	77	386	209	354	304
Restricted Cash	0.69	0.34	0.30	0.30	0.30	0.30	0.30
Short-Term Investments	393	410	485	382	621	521	530
Accounts Receivable	29	32	30	30	24	30	23
Inventories, net	66	69	67	68	68	62	43
Prepaid Expenses	17	17	17	15	14	14	13
Plant, Property, & Equipment, net	32	35	37	40	40	41	39
Total Noncurrent Assets	834	846	956	976	872	874	866
Goodwill	369	369	462	464	410	410	410
Intangible Assets	436	443	450	462	410	410	410
Other Noncurrent Operating Assets	27	32	41	48	50	52	43
Other Noncurrent Nonoperating Assets	1.53	1.92	2.42	2.42	2.42	2.92	2.92
Total Liabilities & Shareholders' Equity	1,450	1,509	1,670	1,898	1,848	1,896	1,819
Total Liabilities	997	1,017	1,021	1,135	1,206	1,204	1,192
Total Current Liabilities	60	78	73	184	271	266	82
Accounts Payable	12	17	21	16	17	17	13
Accrued Expenses	19	22	22	35	27	19	25
Current Deferred Revenue	17	19	17	22	25	31	31
Other Current Liabilities	11	19	13	15	17	14	13
Total Noncurrent Liabilities	937	938	948	951	934	939	1,111
Long-Term Debt	893	893	893	892	892	897	897
Noncurrent Deferred Revenue	5.46	5.71	6.13	5.05	4.99	1.85	1.76
Other Noncurrent Operating Liabilities	38	40	49	54	37	40	212
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	453	493	649	764	642	692	627
Total Preferred & Common Equity	453	493	649	764	642	692	627
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	453	493	649	764	642	692	627
Common Stock	2,603	2,584	2,567	2,523	2,335	2,314	2,081
Retained Earnings	-2,151	-2,091	-1,917	-1,757	-1,690	-1,620	-1,448
Accumulated Other Comprehensive Income / (Loss)	1.55	-0.52	-0.31	-1.84	-2.69	-1.92	-6.26

This table displays calculated financial ratios and metrics derived from Pacific Biosciences of California's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	53.61%	56.29%	-1.69%
EBITDA Growth	-42.39%	-1.98%	-14.48%
EBIT Growth	-49.29%	-0.74%	-14.19%
NOPAT Growth	-41.81%	-8.88%	-45.98%
Net Income Growth	-1.02%	2.39%	-73.40%
EPS Growth	-31.41%	13.57%	-57.30%
Operating Cash Flow Growth	20.49%	1.53%	-136.74%
Free Cash Flow Firm Growth	60.12%	22.19%	43.87%
Invested Capital Growth	-20.58%	12.06%	34.28%
Revenue Q/Q Growth	77.90%	18.29%	-6.33%
EBITDA Q/Q Growth	-20.64%	11.64%	-6.06%
EBIT Q/Q Growth	-18.33%	9.65%	-5.19%
NOPAT Q/Q Growth	-16.02%	-0.14%	-7.87%
Net Income Q/Q Growth	21.41%	0.77%	-5.03%
EPS Q/Q Growth	-8.90%	4.72%	-4.48%
Operating Cash Flow Q/Q Growth	11.55%	1.15%	-12.31%
Free Cash Flow Firm Q/Q Growth	24.27%	36.30%	-85.99%
Invested Capital Q/Q Growth	-12.71%	-2.24%	24.88%
Profitability Metrics	-	-	-
Gross Margin	12.10%	26.32%	38.22%
EBITDA Margin	-133.18%	-143.67%	-220.17%
Operating Margin	-153.98%	-166.80%	-239.43%
EBIT Margin	-146.26%	-150.50%	-233.48%
Profit (Net Income) Margin	-100.59%	-152.97%	-244.92%
Tax Burden Percent	100.10%	96.41%	100.00%
Interest Burden Percent	68.70%	105.43%	104.90%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-38.58%	-25.79%	-28.79%
ROIC Less NNEP Spread (ROIC-NNEP)	-29.94%	-52.13%	-170.71%
Return on Net Nonoperating Assets (RNNOA)	-12.73%	-22.73%	-17.63%
Return on Equity (ROE)	-51.30%	-48.53%	-46.42%
Cash Return on Invested Capital (CROIC)	-15.63%	-37.17%	-58.06%
Operating Return on Assets (OROA)	-29.97%	-17.18%	-15.87%
Return on Assets (ROA)	-20.61%	-17.46%	-16.65%
Return on Common Equity (ROCE)	-51.30%	-48.53%	-46.42%
Return on Equity Simple (ROE_SIMPLE)	-61.16%	-43.74%	-55.83%
Net Operating Profit after Tax (NOPAT)	-332	-234	-215
NOPAT Margin	-107.79%	-116.76%	-167.60%
Net Nonoperating Expense Percent (NNEP)	-8.64%	26.34%	141.92%
Return On Investment Capital (ROIC_SIMPLE)	-28.77%	-14.69%	-13.18%
Cost of Revenue to Revenue	37.90%	73.68%	61.78%
SG&A Expenses to Revenue	56.82%	84.69%	125.37%
R&D to Revenue	43.80%	93.34%	150.42%
Operating Expenses to Revenue	166.09%	193.12%	277.65%
Earnings before Interest and Taxes (EBIT)	-451	-302	-300
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-410	-288	-282
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	0.99	3.74	3.29
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.63	13.08	14.42
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.99	3.01	2.51
Enterprise Value to Revenue (EV/Rev)	2.46	14.38	16.72
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.28	1.27	1.90
Long-Term Debt to Equity	1.28	1.27	1.59
Financial Leverage	0.43	0.44	0.10
Leverage Ratio	2.49	2.78	2.79
Compound Leverage Factor	1.71	2.93	2.92
Debt to Total Capital	56.10%	55.99%	65.50%
Short-Term Debt to Total Capital	0.00%	0.00%	10.55%
Long-Term Debt to Total Capital	56.10%	55.99%	54.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	43.90%	44.01%	34.50%
Debt to EBITDA	-1.58	-3.10	-3.78
Net Debt to EBITDA	-0.63	-0.90	-1.05
Long-Term Debt to EBITDA	-1.58	-3.10	-3.17
Debt to NOPAT	-1.95	-3.81	-4.97
Net Debt to NOPAT	-0.77	-1.11	-1.38
Long-Term Debt to NOPAT	-1.95	-3.81	-4.17
Altman Z-Score	-2.51	0.02	-0.38
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.48	7.81	3.24
Quick Ratio	6.30	7.03	3.00
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-135	-337	-434
Operating Cash Flow to CapEx	-3,329.96%	-2,930.83%	-1,571.41%
Free Cash Flow to Firm to Interest Expense	-10.03	-20.60	-29.52
Operating Cash Flow to Interest Expense	-15.36	-15.83	-17.92
Operating Cash Flow Less CapEx to Interest Expense	-15.83	-16.37	-19.06
Efficiency Ratios	-	-	-
Asset Turnover	0.20	0.11	0.07
Accounts Receivable Turnover	9.61	7.24	5.96
Inventory Turnover	2.02	2.76	2.11
Fixed Asset Turnover	9.20	5.14	3.46
Accounts Payable Turnover	7.38	10.91	6.88
Days Sales Outstanding (DSO)	38.00	50.42	61.20
Days Inventory Outstanding (DIO)	180.47	132.24	172.63
Days Payable Outstanding (DPO)	49.49	33.46	53.02
Cash Conversion Cycle (CCC)	168.98	149.20	180.81
Capital & Investment Metrics	-	-	-
Invested Capital	762	959	856
Invested Capital Turnover	0.36	0.22	0.17
Increase / (Decrease) in Invested Capital	-197	103	219
Enterprise Value (EV)	758	2,884	2,146
Market Capitalization	501	2,624	1,850
Book Value per Share	$1.85	$2.62	$2.49
Tangible Book Value per Share	($0.73)	($0.81)	($1.14)
Total Capital	1,154	1,594	1,632
Total Debt	647	892	1,069
Total Long-Term Debt	647	892	897
Net Debt	257	261	296
Capital Expenditures (CapEx)	6.19	8.84	17
Debt-free, Cash-free Net Working Capital (DFCFNWC)	39	15	-12
Debt-free Net Working Capital (DFNWC)	429	647	761
Net Working Capital (NWC)	429	647	589
Net Nonoperating Expense (NNE)	-22	73	99
Net Nonoperating Obligations (NNO)	255	258	293
Total Depreciation and Amortization (D&A)	40	14	17
Debt-free, Cash-free Net Working Capital to Revenue	12.58%	7.63%	-9.19%
Debt-free Net Working Capital to Revenue	139.40%	322.67%	592.99%
Net Working Capital to Revenue	139.40%	322.67%	458.86%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.13)	($1.21)	($1.40)
Adjusted Weighted Average Basic Shares Outstanding	274.49M	253.63M	224.55M
Adjusted Diluted Earnings per Share	($1.59)	($1.21)	($1.40)
Adjusted Weighted Average Diluted Shares Outstanding	288.37M	253.63M	224.55M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	297.85M	267.95M	247.08M
Normalized Net Operating Profit after Tax (NOPAT)	-203	-217	-213
Normalized NOPAT Margin	-66.05%	-108.35%	-166.30%
Pre Tax Income Margin	-100.49%	-158.67%	-244.92%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-33.59	-18.43	-20.39
NOPAT to Interest Expense	-24.76	-14.30	-14.64
EBIT Less CapEx to Interest Expense	-34.05	-18.97	-21.53
NOPAT Less CapEx to Interest Expense	-25.22	-14.84	-15.78
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Pacific Biosciences of California's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	231.13%	-28.23%	-24.30%	-0.23%	113.35%	72.36%	34.13%	17.26%	-24.06%	-7.38%
EBITDA Growth	-99.94%	39.07%	-151.07%	18.78%	16.26%	-11.84%	6.46%	-12.84%	-39.75%	7.94%
EBIT Growth	-88.17%	22.71%	-164.26%	11.59%	9.09%	-0.93%	5.48%	-8.46%	-34.78%	1.75%
NOPAT Growth	-120.34%	22.32%	-140.31%	10.84%	-0.53%	-10.55%	-7.66%	-17.71%	-34.65%	-0.19%
Net Income Growth	102.89%	9.19%	-148.19%	11.18%	2.80%	13.12%	2.19%	-8.00%	-21.72%	-565.31%
EPS Growth	-41.94%	15.38%	-128.57%	19.44%	16.22%	23.53%	12.50%	2.70%	-19.35%	-525.00%
Operating Cash Flow Growth	46.75%	30.25%	-30.00%	20.07%	4.96%	-3.37%	31.08%	-19.82%	-91.01%	-55.09%
Free Cash Flow Firm Growth	137.95%	118.01%	58.52%	53.23%	41.13%	-311.08%	63.34%	57.95%	58.31%	89.06%
Invested Capital Growth	-20.58%	-11.06%	-1.58%	9.13%	12.06%	43.16%	31.31%	35.12%	34.28%	5.18%
Revenue Q/Q Growth	383.49%	10.98%	-7.21%	-33.50%	4.79%	17.06%	22.30%	42.21%	-15.34%	-8.90%
EBITDA Q/Q Growth	-217.79%	72.22%	-138.71%	5.12%	3.16%	-14.47%	22.78%	2.18%	-29.34%	4.26%
EBIT Q/Q Growth	-160.48%	66.32%	-127.57%	5.76%	-7.00%	-15.16%	23.87%	3.10%	-18.79%	-7.85%
NOPAT Q/Q Growth	-201.05%	63.56%	-116.13%	7.07%	-6.13%	-12.73%	19.81%	-4.79%	-16.70%	-9.79%
Net Income Q/Q Growth	103.90%	64.96%	-121.70%	4.68%	-22.65%	4.24%	20.66%	-4.30%	-9.63%	-7.81%
EPS Q/Q Growth	-100.00%	65.63%	-120.69%	6.45%	-19.23%	7.14%	22.22%	2.70%	-8.82%	-6.25%
Operating Cash Flow Q/Q Growth	32.58%	16.22%	28.30%	-31.48%	11.69%	-56.16%	55.92%	-56.34%	3.94%	-4.11%
Free Cash Flow Firm Q/Q Growth	-1.93%	158.39%	21.38%	15.72%	53.46%	-34.52%	11.35%	-6.08%	-224.97%	88.01%
Invested Capital Q/Q Growth	-12.71%	-0.07%	-10.59%	1.83%	-2.24%	10.58%	-0.86%	4.56%	24.88%	1.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	5.21%	25.03%	16.49%	29.07%	16.40%	32.15%	32.68%	25.09%	18.79%	41.93%
EBITDA Margin	-72.65%	-110.54%	-441.59%	-171.66%	-120.32%	-130.20%	-133.14%	-210.86%	-306.56%	-200.64%
Operating Margin	-79.19%	-160.32%	-488.28%	-209.64%	-150.02%	-148.12%	-153.82%	-234.58%	-318.37%	-230.94%
EBIT Margin	-77.09%	-143.09%	-471.43%	-192.23%	-135.66%	-132.85%	-135.05%	-216.93%	-318.37%	-226.88%
Profit (Net Income) Margin	1.23%	-151.94%	-481.27%	-201.44%	-140.55%	-120.07%	-146.79%	-226.26%	-308.50%	-238.22%
Tax Burden Percent	88.24%	100.00%	100.00%	100.00%	99.13%	86.20%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	-1.80%	106.19%	102.09%	104.79%	104.51%	104.85%	108.70%	104.30%	96.90%	105.00%
Effective Tax Rate	11.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-25.01%	-20.96%	-73.32%	-31.42%	-23.20%	-21.09%	-20.13%	-28.26%	-38.29%	-33.11%
ROIC Less NNEP Spread (ROIC-NNEP)	28.51%	-25.94%	-89.36%	-39.42%	-30.72%	-27.68%	-35.67%	-65.10%	-71.80%	4.92%
Return on Net Nonoperating Assets (RNNOA)	12.12%	-13.59%	-49.32%	-15.61%	-13.40%	-5.51%	-6.45%	-5.98%	-7.41%	-0.44%
Return on Equity (ROE)	-12.89%	-34.55%	-122.64%	-47.03%	-36.59%	-26.60%	-26.58%	-34.24%	-45.70%	-33.55%
Cash Return on Invested Capital (CROIC)	-15.63%	-19.16%	-32.37%	-33.00%	-37.17%	-63.55%	-56.28%	-58.71%	-58.06%	-34.87%
Operating Return on Assets (OROA)	-15.80%	-14.80%	-53.05%	-21.61%	-15.49%	-12.12%	-10.60%	-15.17%	-21.65%	-16.13%
Return on Assets (ROA)	0.25%	-15.71%	-54.15%	-22.64%	-16.04%	-10.95%	-11.52%	-15.82%	-20.98%	-16.94%
Return on Common Equity (ROCE)	-12.89%	-34.55%	-122.64%	-47.03%	-36.59%	-26.60%	-26.58%	-34.24%	-45.70%	-33.55%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-87.01%	-81.26%	-45.75%	0.00%	-40.47%	-49.72%	-46.35%	0.00%	-47.75%
Net Operating Profit after Tax (NOPAT)	-135	-45	-123	-57	-61	-58	-51	-64	-61	-52
NOPAT Margin	-69.88%	-112.23%	-341.80%	-146.75%	-105.02%	-103.69%	-107.67%	-164.21%	-222.86%	-161.66%
Net Nonoperating Expense Percent (NNEP)	-53.52%	4.98%	16.04%	7.99%	7.52%	6.60%	15.54%	36.84%	33.51%	-38.04%
Return On Investment Capital (ROIC_SIMPLE)	-11.70%	-	-	-	-3.85%	-	-	-	-3.74%	-
Cost of Revenue to Revenue	15.09%	74.97%	83.51%	70.93%	83.60%	67.85%	67.32%	74.91%	81.21%	58.07%
SG&A Expenses to Revenue	21.55%	109.46%	127.39%	112.74%	78.82%	77.99%	85.29%	102.36%	164.53%	113.88%
R&D to Revenue	14.21%	63.84%	106.86%	111.97%	76.33%	85.32%	97.06%	125.81%	155.83%	145.75%
Operating Expenses to Revenue	84.40%	185.36%	504.77%	238.71%	166.42%	180.27%	186.49%	259.67%	337.16%	272.87%
Earnings before Interest and Taxes (EBIT)	-149	-57	-170	-75	-79	-74	-64	-84	-87	-73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-140	-44	-159	-67	-70	-73	-63	-82	-84	-65
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.99	1.02	0.76	1.55	3.74	2.74	5.18	4.13	3.29	2.08
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.63	2.68	1.98	5.01	13.08	12.34	22.74	21.35	14.42	9.53
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.99	1.01	0.87	1.37	3.01	2.36	4.02	3.43	2.51	1.99
Enterprise Value to Revenue (EV/Rev)	2.46	5.11	4.00	6.66	14.38	13.64	24.44	22.88	16.72	9.98
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.28	1.97	1.81	1.38	1.27	1.29	1.68	1.56	1.90	1.43
Long-Term Debt to Equity	1.28	1.97	1.81	1.38	1.27	1.17	1.39	1.30	1.59	1.43
Financial Leverage	0.43	0.52	0.55	0.40	0.44	0.20	0.18	0.09	0.10	-0.09
Leverage Ratio	2.49	2.75	2.96	2.66	2.78	2.67	2.81	2.69	2.79	2.63
Compound Leverage Factor	-0.04	2.92	3.02	2.79	2.90	2.80	3.06	2.80	2.70	2.76
Debt to Total Capital	56.10%	66.34%	64.44%	57.90%	55.99%	56.41%	62.68%	60.97%	65.50%	58.86%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	5.49%	10.83%	10.40%	10.55%	0.00%
Long-Term Debt to Total Capital	56.10%	66.34%	64.44%	57.90%	55.99%	50.92%	51.85%	50.57%	54.95%	58.86%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	43.90%	33.66%	35.56%	42.10%	44.01%	43.59%	37.32%	39.03%	34.50%	41.14%
Debt to EBITDA	-1.58	-2.63	-2.42	-3.27	-3.10	-3.03	-3.46	-3.71	-3.78	-3.37
Net Debt to EBITDA	-0.63	-1.24	-1.04	-1.21	-0.90	-0.68	-0.80	-0.71	-1.05	-0.23
Long-Term Debt to EBITDA	-1.58	-2.63	-2.42	-3.27	-3.10	-2.74	-2.87	-3.07	-3.17	-3.37
Debt to NOPAT	-1.95	-3.12	-2.99	-3.93	-3.81	-4.23	-4.72	-4.81	-4.97	-4.50
Net Debt to NOPAT	-0.77	-1.47	-1.28	-1.45	-1.11	-0.94	-1.09	-0.92	-1.38	-0.31
Long-Term Debt to NOPAT	-1.95	-3.12	-2.99	-3.93	-3.81	-3.82	-3.91	-3.99	-4.17	-4.50
Altman Z-Score	-1.72	-1.38	-1.53	-0.61	0.44	0.21	0.77	0.61	0.02	0.03
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.48	9.74	8.01	9.28	7.81	4.80	3.45	3.69	3.24	11.19
Quick Ratio	6.30	8.34	6.92	8.12	7.03	4.34	3.15	3.40	3.00	10.50
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	62	64	-109	-139	-165	-354	-263	-297	-280	-86
Operating Cash Flow to CapEx	-1,895.49%	0.00%	-3,668.90%	-1,951.07%	-2,843.87%	-7,853.13%	-1,840.43%	-2,544.77%	-1,235.03%	-1,505.20%
Free Cash Flow to Firm to Interest Expense	22.65	18.00	-30.78	-38.79	-46.08	-98.55	-47.05	-81.69	-76.63	-23.48
Operating Cash Flow to Interest Expense	-11.12	-12.85	-15.32	-21.17	-16.12	-18.17	-7.47	-26.09	-16.60	-17.21
Operating Cash Flow Less CapEx to Interest Expense	-11.70	-12.63	-15.74	-22.25	-16.69	-18.40	-7.88	-27.11	-17.95	-18.35
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.20	0.10	0.11	0.11	0.11	0.09	0.08	0.07	0.07	0.07
Accounts Receivable Turnover	9.61	5.78	6.69	6.69	7.24	6.37	5.72	4.67	5.96	5.87
Inventory Turnover	2.02	2.04	2.12	2.26	2.76	2.17	1.97	1.95	2.11	2.47
Fixed Asset Turnover	9.20	4.79	5.02	5.13	5.14	4.26	3.73	3.51	3.46	3.90
Accounts Payable Turnover	7.38	9.68	8.48	7.61	10.91	8.37	6.95	5.11	6.88	8.57
Days Sales Outstanding (DSO)	38.00	63.10	54.56	54.55	50.42	57.32	63.81	78.21	61.20	62.23
Days Inventory Outstanding (DIO)	180.47	179.34	172.40	161.48	132.24	168.32	185.33	186.97	172.63	147.73
Days Payable Outstanding (DPO)	49.49	37.70	43.04	47.95	33.46	43.62	52.52	71.45	53.02	42.60
Cash Conversion Cycle (CCC)	168.98	204.74	183.93	168.08	149.20	182.02	196.62	193.73	180.81	167.36
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	762	873	873	977	959	981	888	895	856	686
Invested Capital Turnover	0.36	0.19	0.21	0.21	0.22	0.20	0.19	0.17	0.17	0.20
Increase / (Decrease) in Invested Capital	-197	-109	-14	82	103	296	212	233	219	34
Enterprise Value (EV)	758	885	756	1,335	2,884	2,312	3,572	3,067	2,146	1,367
Market Capitalization	501	463	373	1,005	2,624	2,092	3,324	2,861	1,850	1,305
Book Value per Share	$1.85	$1.66	$1.81	$2.42	$2.62	$3.05	$2.57	$2.80	$2.49	$2.79
Tangible Book Value per Share	($0.73)	($1.29)	($1.17)	($0.98)	($0.81)	($0.65)	($0.71)	($0.52)	($1.14)	($0.86)
Total Capital	1,154	1,346	1,386	1,542	1,594	1,752	1,720	1,773	1,632	1,523
Total Debt	647	893	893	893	892	988	1,078	1,081	1,069	897
Total Long-Term Debt	647	893	893	893	892	892	892	897	897	897
Net Debt	257	421	383	330	261	220	248	206	296	62
Capital Expenditures (CapEx)	1.62	-0.79	1.48	3.88	2.02	0.83	2.27	3.72	4.90	4.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	39	52	40	42	15	26	20	25	-12	-2.39
Debt-free Net Working Capital (DFNWC)	429	524	550	604	647	795	850	900	761	832
Net Working Capital (NWC)	429	524	550	604	647	698	664	715	589	832
Net Nonoperating Expense (NNE)	-137	16	50	21	21	9.12	19	24	23	25
Net Nonoperating Obligations (NNO)	255	420	381	328	258	218	246	203	293	59
Total Depreciation and Amortization (D&A)	8.57	13	11	7.98	8.95	1.48	0.91	2.36	3.23	8.48
Debt-free, Cash-free Net Working Capital to Revenue	12.58%	30.26%	20.97%	20.88%	7.63%	15.60%	13.90%	18.35%	-9.19%	-1.75%
Debt-free Net Working Capital to Revenue	139.40%	302.77%	291.07%	301.39%	322.67%	468.70%	581.97%	671.33%	592.99%	607.61%
Net Working Capital to Revenue	139.40%	302.77%	291.07%	301.39%	322.67%	411.96%	454.47%	533.78%	458.86%	607.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.02	($0.22)	($0.64)	($0.29)	($0.31)	($0.26)	($0.28)	($0.36)	($0.37)	($0.34)
Adjusted Weighted Average Basic Shares Outstanding	274.49M	272.92M	272.39M	269.58M	253.63M	255.00M	250.07M	242.03M	224.55M	225.12M
Adjusted Diluted Earnings per Share	($0.44)	($0.22)	($0.64)	($0.29)	($0.31)	($0.26)	($0.28)	($0.36)	($0.37)	($0.34)
Adjusted Weighted Average Diluted Shares Outstanding	288.37M	272.92M	272.39M	269.58M	253.63M	255.00M	250.07M	242.03M	224.55M	225.12M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	297.85M	273.86M	272.53M	272.36M	267.95M	267.44M	250.56M	249.89M	247.08M	226.11M
Normalized Net Operating Profit after Tax (NOPAT)	-137	-44	-58	-57	-61	-52	-50	-55	-58	-49
Normalized NOPAT Margin	-70.77%	-110.18%	-160.64%	-146.88%	-103.70%	-92.74%	-104.77%	-142.15%	-211.09%	-152.39%
Pre Tax Income Margin	1.39%	-151.94%	-481.27%	-201.44%	-141.78%	-139.30%	-146.79%	-226.26%	-308.50%	-238.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-54.03	-16.16	-47.93	-20.87	-22.17	-20.62	-11.50	-23.25	-23.87	-20.01
NOPAT to Interest Expense	-48.98	-12.68	-34.75	-15.93	-17.16	-16.09	-9.17	-17.60	-16.71	-14.26
EBIT Less CapEx to Interest Expense	-54.62	-15.94	-48.35	-21.95	-22.74	-20.85	-11.91	-24.27	-25.22	-21.15
NOPAT Less CapEx to Interest Expense	-49.56	-12.46	-35.17	-17.02	-17.73	-16.33	-9.57	-18.62	-18.05	-15.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Pacific Biosciences of California's Financials

When does Pacific Biosciences of California's fiscal year end?

According to the most recent income statement we have on file, Pacific Biosciences of California's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Pacific Biosciences of California's net income changed over the last 2 years?

The last 5 years of Pacific Biosciences of California's net income performance:

2022: -$314.25 million
2023: -$306.74 million
2024: -$309.85 million

Find out what analysts predict for Pacific Biosciences of California in the coming months.

What is Pacific Biosciences of California's operating income?

Pacific Biosciences of California's total operating income in 2024 was -$474.31 million, based on the following breakdown:

Total Gross Profit: $37.28 million
Total Operating Expenses: $511.60 million

How has Pacific Biosciences of California revenue changed over the last 2 years?

Over the last 2 years, Pacific Biosciences of California's total revenue changed from $128.30 million in 2022 to $308.03 million in 2024, a change of 140.1%.

How much debt does Pacific Biosciences of California have?

Pacific Biosciences of California's total liabilities were at $753.85 million at the end of 2024, a 27.8% decrease from 2023, and a 37.4% decrease since 2022.

How much cash does Pacific Biosciences of California have?

In the past 2 years, Pacific Biosciences of California's cash and equivalents has ranged from $55.37 million in 2024 to $325.09 million in 2022, and is currently $55.37 million as of their latest financial filing in 2024.

How has Pacific Biosciences of California's book value per share changed over the last 2 years?

Over the last 2 years, Pacific Biosciences of California's book value per share changed from 2.49 in 2022 to 1.85 in 2024, a change of -25.7%.

Related Companies

This page (NASDAQ:PACB) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Financials

Frequently Asked Questions About Pacific Biosciences of California's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Financials

Annual Income Statements for Pacific Biosciences of California

Quarterly Income Statements for Pacific Biosciences of California

Annual Cash Flow Statements for Pacific Biosciences of California

Quarterly Cash Flow Statements for Pacific Biosciences of California

Annual Balance Sheets for Pacific Biosciences of California

Quarterly Balance Sheets for Pacific Biosciences of California

Annual Metrics And Ratios for Pacific Biosciences of California

Quarterly Metrics And Ratios for Pacific Biosciences of California

Frequently Asked Questions About Pacific Biosciences of California's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools